Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

BACKGROUND: Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Brempelis, Katherine J, Cowan, Courtney M, Kreuser, Shannon A, Labadie, Kevin P, Prieskorn, Brooke M, Lieberman, Nicole A P, Ene, Chibawanye I, Moyes, Kara W, Chinn, Harrison, DeGolier, Kole R, Matsumoto, Lisa R, Daniel, Sara K, Yokoyama, Jason K, Davis, Amira D, Hoglund, Virginia J, Smythe, Kimberly S, Balcaitis, Stephanie D, Jensen, Michael C, Ellenbogen, Richard G, Campbell, Jean S, Pierce, Robert H, Holland, Eric C, Pillarisetty, Venu G, Crane, Courtney A
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Immune Cell Therapies and Immune Cell Engineering
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594542/
https://ncbi.nlm.nih.gov/pubmed/33115946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001356
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы